Literature DB >> 21227528

Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus.

Naoya Kawano1, Katsuhito Mori, Masanori Emoto, Eiko Lee, Ikue Kobayashi, Yuko Yamazaki, Hiromi Urata, Tomoaki Morioka, Hidenori Koyama, Tetsuo Shoji, Yoshiki Nishizawa, Masaaki Inaba.   

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) was originally isolated as an inducer of apoptosis. Recent cross-sectional and prospective studies suggest an inverse association of serum TRAIL levels with the severity of coronary artery disease (CAD) and with an adverse outcome in patients with CAD or heart failure. However, it is unknown whether TRAIL can inversely reflect the progression of atherosclerosis from its early stage. We therefore examined the association between TRAIL measured by ELISA and intima-media thickness (IMT) in carotid and femoral arteries evaluated by ultrasonography as a surrogate marker of atherosclerosis in 416 type 2 diabetic patients without any symptoms of CAD and heart failure. Concurrently, the existence of calcified plaque (CP) was examined. There was no significant association between TRAIL and carotid IMT (ρ=-0.096, p=0.052) or femoral IMT (ρ=-0.025, p=0.610), although TRAIL was associated with carotid IMT in a subset of patients with macrovascular diseases (ρ=-0.174, p=0.034). No difference in TRAIL levels was found between two groups with or without CP. TRAIL may not be a good candidate as a biomarker to evaluate early-stage atherosclerotic lesions.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21227528     DOI: 10.1016/j.diabres.2010.11.034

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  11 in total

1.  The relationship between circulating TRAIL and endothelial dysfunction in subclinical hypothyroidism.

Authors:  Guangda Xiang; Ling Yue; Junxia Zhang; Lin Xiang; Jing Dong
Journal:  Endocrine       Date:  2014-10-08       Impact factor: 3.633

2.  Circulating TRAIL shows a significant post-partum decline associated to stressful conditions.

Authors:  Giorgio Zauli; Lorenzo Monasta; Erika Rimondi; Liza Vecchi Brumatti; Oriano Radillo; Luca Ronfani; Marcella Montico; Giuseppina D'Ottavio; Salvatore Alberico; Paola Secchiero
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

3.  TRAIL attenuates RANKL-mediated osteoblastic signalling in vascular cell mono-culture and co-culture models.

Authors:  Emma Harper; Keith D Rochfort; Hannah Forde; Colin Davenport; Diarmuid Smith; Philip M Cummins
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

Review 4.  TRAIL and Cardiovascular Disease-A Risk Factor or Risk Marker: A Systematic Review.

Authors:  Katarzyna Kakareko; Alicja Rydzewska-Rosołowska; Edyta Zbroch; Tomasz Hryszko
Journal:  J Clin Med       Date:  2021-03-18       Impact factor: 4.241

5.  Association of soluble Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) with central adiposity and low-density lipoprotein cholesterol.

Authors:  Gloria Brombo; Stefano Volpato; Paola Secchiero; Angelina Passaro; Cristina Bosi; Giovanni Zuliani; Giorgio Zauli
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

6.  Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers.

Authors:  Hasan Onur Arık; Arzu Didem Yalcin; Saadet Gumuslu; Gizem Esra Genç; Adil Turan; Ahter Dilsad Sanlioglu
Journal:  Med Sci Monit       Date:  2013-08-29

7.  Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry.

Authors:  Carlo Cervellati; Paola Secchiero; Gloria Bonaccorsi; Claudio Celeghini; Giorgio Zauli
Journal:  Mediators Inflamm       Date:  2014-05-21       Impact factor: 4.711

8.  Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect.

Authors:  Fernanda Genre; Raquel López-Mejías; Javier Rueda-Gotor; José A Miranda-Filloy; Begoña Ubilla; Beatriz Carnero-López; Natalia Palmou-Fontana; Inés Gómez-Acebo; Ricardo Blanco; Trinitario Pina; Rodrigo Ochoa; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Mediators Inflamm       Date:  2014-05-21       Impact factor: 4.711

9.  Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia.

Authors:  Wen Cheng; Fangfang Liu; Zhe Wang; Yun Zhang; Yu-Xia Zhao; Qunye Zhang; Fan Jiang
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

Review 10.  Repositioning the Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) on the TRAIL to the Development of Diabetes Mellitus: An Update of Experimental and Clinical Evidence.

Authors:  Chrysi Koliaki; Nicholas Katsilambros
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.